Zhang 2006.
Methods | Randomized trial Eligible patients
|
|
Participants | P arm: 30 participants CisP arm: 34 participants CarP arm: 32 participants Median age of study population: 70 years; 51 with stage IIIB and 45 stage IV disease. PS at baseline not informed. No geriatric data scales collected |
|
Interventions | P arm: paclitaxel 60 mg/m2 i.v. infusion on days 1, 8, and 15, every 4 weeks CisP arm: cisplatin 30 mg/m2 i.v. infusion on days 2 to 4 and paclitaxel 60 mg/m2 i.v. infusion on days 1, 8, and 15, every 4 weeks CarP arm: carboplatin AUC5 i.v. infusion on day 2 and paclitaxel 60 mg/m2 i.v. infusion on days 1, 8, and 15, every 4 weeks |
|
Outcomes | ||
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | No information on random sequence generation |
Allocation concealment (selection bias) | Unclear risk | No information on allocation concealment |
Blinding of outcome assessment (detection bias) OS and 1y OS rate outcome | Unclear risk | No information on blinding of assessors. Study considered to have unclear impact on mortality outcomes |
Blinding of outcome assessment (detection bias) Other outcomes | High risk | No information on blinding of assessors for other outcomes |
Incomplete outcome data (attrition bias) All outcomes | Low risk | No evidence of attrition bias |
Selective reporting (reporting bias) | Low risk | No evidence of reporting bias |
Other bias | Unclear risk | No separate analysis on participants > 70 years |